NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its second quarter net loss swelled year over year as it continues to advance its flagship liquid biopsy test toward commercialization.

For the three months ended June 30, the Alameda, California-based diagnostic developer incurred a net loss of $4.5 million, or $.12 per share, compared to a loss of $3.8 million, or $.13 per share, in the year-ago period. Analysts on average had expected a loss per share of $.09.

OncoCyte did not report any Q2 revenues, the same as in the year-ago quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
06

Rhythm Pharmaceuticals and Genomenon will discuss their efforts to assemble a database of mutations associated with rare genetic disorders of obesity, and how this was optimized to facilitate a deep understanding of the variant landscape of melanocortin-4 receptor (MC4R)-pathway genes. This database may help identify MC4R-pathway deficient individuals who might benefit from future precision therapies.